# US 5,348,887 A · Vectors and DNAS for expression of a human adenocarcinoma antigen > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,348,887 A - Document ID: US5348887A - Status: Granted - Kind: A - Application number: 07/976,301 - Filed: 1992-11-13 - Granted: 1994-09-20 - Earliest claimed: 1988-01-29 - Assignees: Eli Lilly and Company - Inventors: Thomas F. Bumol; Robert A. Gadski; Amy E. Hamilton; J. Richard Sportsiman; Joann Strnad - Web page: https://patentgrep.com/patent/US5348887A ## CPC - C07K 14/82: Translation products from oncogenes - C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)} - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract The present invention comprises novel recombinant DNA compounds which encode the .about.40,000 dalton adenocarcinoma antigen recognized by monoclonal antibody KS 1/4. Eukaryotic and prokaryotic expression vectors have been constructed that comprise novel KSA-encoding DNA and drive expression of KSA when transformed into an appropriate host cell. The novel expression vectors can be used to produce KSA derivatives, such as non-glycosylated KSA, and to produce KSA precursors, such as nascent KSA, and to produce subfragments of KSA. The recombinant-produced KSA is useful for the diagnosis, prognosis and treatment of disease states including adenocarcinomas of the lung, prostate, breast, ovary and colon/rectum; and for the creation of novel antibodies for treatment or diagnosis of the above. ## Claims ### Claim 1 A recombinant DNA encoding mature KSA wherein the coding strand is: ##STR24## wherein A is deoxyadenyl, G is deoxyguanyl, C is deoxycytidyl, and T is thymidyl. ### Claim 2 A recombinant DNA encoding pro KSA wherein the coding strand is: ##STR25## wherein A is deoxyadenyl, G is deoxyguanyl, C is deoxycytidyl, and T is thymidyl. ### Claim 3 A recombinant DNA encoding prepro KSA herein the coding strand is: ##STR26## wherein A is deoxyadenyl, G is deoxyguanyl, C is deoxycytidyl, and T is thymidyl. ### Claim 4 (depends on 1) A recombinant DNA vector that comprises the DNA of claim 1. ### Claim 5 (depends on 2) A recombinant DNA vector that comprises the DNA of claim 2. ### Claim 6 (depends on 3) A recombinant DNA vector that comprises the DNA of claim 3. ### Claim 7 (depends on 6) The recombinant DNA vector of claim 6 that is plasmid pGAG1317. ### Claim 8 (depends on 4) A recombinant DNA expression vector of claim 4 that further comprises a promoter and translational activating sequence positioned to drive expression of said DNA. ### Claim 9 (depends on 5) A recombinant DNA expression vector of claim 5 that further comprises a promoter and translational activating sequence positioned to drive expression of said DNA. ### Claim 10 (depends on 6) A recombinant DNA expression vector of claim 6 that further comprises a promoter and translational activating sequence positioned to drive expression of said DNA. ### Claim 11 (depends on 8) The recombinant DNA expression vector of claim 8, wherein said promoter functions in a eukaryotic cell. ### Claim 12 (depends on 9) The recombinant DNA expression vector of claim 9, wherein said promoter functions in a eukaryotic cell. ### Claim 13 (depends on 10) The recombinant DNA expression vector of claim 10, wherein said promoter functions in a eukaryotic cell. ### Claim 14 (depends on 11) The recombinant DNA expression vector of claim 11, wherein said promoter is the Adenovirus Late Promoter. ### Claim 15 (depends on 12) The recombinant DNA expression vector of claim 12, wherein said promoter is the Adenovirus Late Promoter. ### Claim 16 (depends on 13) The recombinant DNA expression vector of claim 13, wherein said promoter is the Adenovirus Late Promoter. ### Claim 17 (depends on 8) The recombinant DNA expression vector of claim 8, wherein said promoter functions in a prokaryotic cell. ### Claim 18 (depends on 9) The recombinant DNA expression vector of claim 9, wherein said promoter functions in a prokaryotic cell. ### Claim 19 (depends on 10) The recombinant DNA expression vector of claim 10, wherein said promoter functions in a prokaryotic cell. ### Claim 20 (depends on 17) The recombinant DNA expression vector of claim 17, wherein said promoter is the .lambda.pL promoter. ### Claim 21 (depends on 18) The recombinant DNA expression vector of claim 18, wherein said promoter is the .lambda.pL promoter. ### Claim 22 (depends on 19) The recombinant DNA expression vector of claim 19, wherein said promoter is the .lambda.pL promoter. ### Claim 23 A recombinant DNA expression vector that is plasmid pLKSA. ### Claim 24 A recombinant DNA vector selected from the group consisting of plasmids pAG932, pAG1338 and pLKSA-B. ### Claim 25 (depends on 24) The recombinant DNA vector of claim 24 that is pAG932. ### Claim 26 (depends on 24) The recombinant DNA vector of claim 24 that is pAG1338. ### Claim 27 (depends on 24) The recombinant DNA vector of claim 24 that is pLKSA-B.